Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genetic protection bill "could harm Swiss industry":w :

This article was originally published in Clinica

Executive Summary

Biomedical research in Switzerland could grind to a halt if a proposed genetic protection bill is passed, a leading Swiss industrialist has warned. Basic immunology research into illnesses such as cancer, diabetes, multiple sclerosis, HIV and Alzheimer's disease would be unable to continue, claimed Fritz Gerber, chairman of Roche. The bill, he said, would "totally cripple" biomedical research in the country. The proposed bill, the subject of a referendum on June 7, would prohibit the production and sale of genetically modified animals or plants and prevent patents from being granted for any process linked to research involving them.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT081371

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel